Scancell Sets Date for Interim Results as Cancer Immunotherapy Portfolio Advances

Scancell Holdings ( (GB:SCLP) ) has shared an update.

Scancell Holdings will publish its interim financial results for the six months to 31 October 2025, alongside a post-period business update, on 29 January 2026, and management will host a live webcast for analysts and investors the same afternoon. The announcement underscores ongoing clinical and strategic progress across Scancell’s oncology immunotherapy portfolio, including its biomarker-driven development path for melanoma candidate iSCIB1+, the broad Phase 2 programme for Modi-1 in solid tumours, and the external validation of its GlyMab antibody platform through existing licences with Genmab, developments that are likely to be of close interest to investors tracking its transition toward later-stage and potentially registrational studies.

The most recent analyst rating on (GB:SCLP) stock is a Hold with a £13.50 price target. To see the full list of analyst forecasts on Scancell Holdings stock, see the GB:SCLP Stock Forecast page.

Spark’s Take on GB:SCLP Stock

According to Spark, TipRanks’ AI Analyst, GB:SCLP is a Neutral.

The score is held back primarily by weak financial performance (ongoing losses, negative equity, and cash burn), only partly offset by improved burn in 2025. Technicals show an uptrend but are extremely overextended, adding pullback risk. The latest earnings call was comparatively supportive due to strengthened liquidity/runway and pipeline/regulatory progress, while valuation remains difficult to justify using traditional metrics because the company is loss-making.

To see Spark’s full report on GB:SCLP stock, click here.

More about Scancell Holdings

Scancell Holdings is a UK-listed clinical-stage biotechnology company developing targeted, off-the-shelf active immunotherapies for cancer using its proprietary Immunobody and Moditope platforms. Its lead Immunobody product, iSCIB1+, has shown monotherapy activity in adjuvant melanoma and additional benefit when combined with checkpoint inhibitors in the Phase 2 SCOPE trial, supporting a precision biomarker-led registrational strategy. Lead Moditope candidate Modi-1 is being evaluated in a Phase 2 study across multiple solid tumours with encouraging interim data, while subsidiary Glymab Therapeutics is advancing a pipeline of high-affinity GlyMab antibodies against tumour-specific glycans, two of which are already licensed to antibody-therapeutics specialist Genmab.

Average Trading Volume: 1,254,376

Technical Sentiment Signal: Buy

Current Market Cap: £134.9M

Learn more about SCLP stock on TipRanks’ Stock Analysis page.